$Enlivex Therapeutics (ENLV.US)$ NEWS Enlivex Announces Topl...
NEWS
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
Enlivex Therapeutics (ENLV) announces positive results from Phase II study of Allocetra™ in sepsis patients, showing significant reductions in SOFA scores and mortality rates. The study indicates a potential market opportunity for Allocetra™ in high-risk sepsis patients originating from urinary tract infections.
Positive indication of effect and safety results from Phase II study of Allocetra™ in sepsis patients. Substantial reductions in SOFA scores and mortality rates observed in Allocetra™-treated patients. Potential indication of effect of Allocetra™ compared with placebo in high-risk sepsis patient population. Consideration of a follow-on, randomized, controlled study for High Risk UTI sepsis population. Acceptable safety and tolerability profile of Allocetra™ IV infusions across all patient subgroups and risk categories.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
470Followers
66Following
3010Visitors
Follow
73210991 : is this a good news